These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22521646)

  • 1. Novel triazolopyridylbenzamides as potent and selective p38α inhibitors.
    Aiguadé J; Balagué C; Carranco I; Caturla F; Domínguez M; Eastwood P; Esteve C; González J; Lumeras W; Orellana A; Preciado S; Roca R; Vidal L; Vidal B
    Bioorg Med Chem Lett; 2012 May; 22(10):3431-6. PubMed ID: 22521646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.
    Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzothiazole based inhibitors of p38alpha MAP kinase.
    Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.
    Michelotti EL; Moffett KK; Nguyen D; Kelly MJ; Shetty R; Chai X; Northrop K; Namboodiri V; Campbell B; Flynn GA; Fujimoto T; Hollinger FP; Bukhtiyarova M; Springman EB; Karpusas M
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5274-9. PubMed ID: 16169718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
    Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode.
    Eastwood P; González J; Gómez E; Vidal B; Caturla F; Roca R; Balagué C; Orellana A; Domínguez M
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4130-3. PubMed ID: 21696951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
    Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
    Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
    Swann SL; Merta PJ; Kifle L; Groebe D; Sarris K; Hajduk PJ; Sun C
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5787-92. PubMed ID: 20471255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
    Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors.
    Martz KE; Dorn A; Baur B; Schattel V; Goettert MI; Mayer-Wrangowski SC; Rauh D; Laufer SA
    J Med Chem; 2012 Sep; 55(17):7862-74. PubMed ID: 22897496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.